.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Teva
McKesson
Farmers Insurance
Colorcon
Dow
Chinese Patent Office
Express Scripts
Fish and Richardson
QuintilesIMS

Generated: December 15, 2017

DrugPatentWatch Database Preview

Oak Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OAK PHARMS, and when can generic versions of OAK PHARMS drugs launch?

OAK PHARMS has fifteen approved drugs.

There are seven US patents protecting OAK PHARMS drugs on OAK PHARMS drugs in the past three years.

There are sixty-six patent family members on OAK PHARMS drugs in twenty-two countries and twenty-eight supplementary protection certificates in ten countries.

Summary for Oak Pharms

International Patents:66
US Patents:7
Tradenames:11
Ingredients:11
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Oak Pharms AkornDIURILchlorothiazideTABLET;ORAL011145-004Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncAZASITEazithromycinSOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Oak Pharms IncZIOPTANtafluprostSOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Oak Pharms AkornCOGENTINbenztropine mesylateINJECTABLE;INJECTION012015-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak PharmsNEMBUTALpentobarbital sodiumSUPPOSITORY;RECTAL083247-002Jan 25, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Oak PharmsNEMBUTAL SODIUMpentobarbital sodiumCAPSULE;ORAL084095-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncZIOPTANtafluprostSOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncAZASITEazithromycinSOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncCOSOPT PFdorzolamide hydrochloride; timolol maleateSOLUTION/DROPS;OPHTHALMIC202667-001Feb 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Oak Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002► Subscribe► Subscribe
Oak Pharms IncCOSOPTdorzolamide hydrochloride; timolol maleateSOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999► Subscribe► Subscribe
Oak Pharms IncBETIMOLtimololSOLUTION/DROPS;OPHTHALMIC020439-002Mar 31, 1995► Subscribe► Subscribe
Oak Pharms IncAZASITEazithromycinSOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-001Mar 25, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for OAK PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
tafluprostOphthalmic Solution0.0015%ZIOPTAN2/10/2016
levalbuterol tartrateInhalation Aerosol0.045 mg/actuationXOPENEX2/27/2012
azithromycinOphthalmic Solution1%AZASITE3/3/2011
levalbuterol hydrochlorideInhalation Solution0.0025XOPENEX5/23/2006
dorzolamide hydrochloride and timolol maleateOphthalmic Solution2%/0.5%COSOPT10/11/2005
levalbuterol hydrochlorideInhalation Solution0.0103%, 0.021% and 0.042%XOPENEX6/20/2005

Non-Orange Book Patents for Oak Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,920 Difluoroprostaglandin derivatives and their use► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
6,699,492 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Oak Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office1165058► Subscribe
Austria271390► Subscribe
Germany60020351► Subscribe
Japan2004002462► Subscribe
Japan2010083901► Subscribe
Norway317060► Subscribe
European Patent Office0850926► Subscribe
Germany69825128► Subscribe
Canada2368637► Subscribe
Portugal1028707► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Oak Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/005United Kingdom► SubscribePRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
C0020France► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
2008 00041Denmark► Subscribe
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C0020France► SubscribePRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0850926/01Switzerland► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Harvard Business School
US Army
Healthtrust
Colorcon
Argus Health
Johnson and Johnson
Julphar
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot